We are live on ! Find out more
EW icon

Edwards Lifesciences

556 hedge funds and large institutions have $11.7B invested in Edwards Lifesciences in 2014 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 193 increasing their positions, 182 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 1015 (+5)

12% more funds holding

Funds holding: 496556 (+60)

6% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 182

5% less capital invested

Capital invested by funds: $12.4B → $11.7B (-$651M)

7.78% less ownership

Funds ownership: 523.44%515.66% (-7.8%)

15% less call options, than puts

Call options by funds: $44.3M | Put options by funds: $52.1M

Holders
556
Holders Change
+60
Holders Change %
+12.1%
% of All Funds
14.83%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.4%
New
97
Increased
193
Reduced
182
Closed
31
Calls
$44.3M
Puts
$52.1M
Net Calls
-$7.8M
Net Calls Change
-$17.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Kayne Anderson Rudnick Investment Management
301
Kayne Anderson Rudnick Investment Management
California
$1.52M -$114K -5,664 -7%
DWA
302
Dorsey Wright & Associates
California
$1.48M +$1.4M +69,906 New
Bessemer Group
303
Bessemer Group
New Jersey
$1.47M +$1.39M +69,210 New
MOACM
304
Mutual of America Capital Management
New York
$1.46M +$24K +1,194 +2%
BKBG
305
BHF Kleinwort Benson Group
Belgium
$1.45M +$784K +39,000 +138%
JDR
306
Jay D. Rosenbaum
$1.44M +$1.36M +67,800 New
Nomura Asset Management
307
Nomura Asset Management
Japan
$1.41M -$12.1K -600 -0.9%
Zurich Cantonal Bank
308
Zurich Cantonal Bank
Switzerland
$1.39M +$336K +16,740 +34%
GL
309
GLG LLC
New York
$1.37M
KCM
310
Kames Capital Management
United Kingdom
$1.36M
DSI
311
Daiwa SB Investments
Japan
$1.35M -$1.53M -76,044 -54%
LPL Financial
312
LPL Financial
California
$1.35M +$331K +16,500 +35%
SCM
313
Shelton Capital Management
Colorado
$1.35M +$591K +29,442 +87%
Commonwealth Equity Services
314
Commonwealth Equity Services
Massachusetts
$1.33M +$168K +8,370 +15%
WMSA
315
Weiss Multi-Strategy Advisers
New York
$1.27M -$362K -18,000 -23%
DM
316
Deerfield Management
New York
$1.27M +$1.21M +60,000 New
Creative Planning
317
Creative Planning
Kansas
$1.26M +$587K +29,238 +96%
GMIM
318
General Motors Investment Management
New York
$1.25M -$213K -10,590 -15%
SAM
319
Securian Asset Management
Minnesota
$1.24M +$36.9K +1,836 +3%
SMDAM
320
Sumitomo Mitsui DS Asset Management
Japan
$1.19M -$67.3K -3,348 -6%
TRIM
321
Thompson Rubinstein Investment Management
Oregon
$1.13M -$5.45M -271,482 -84%
FIM
322
Freedom Investment Management
Connecticut
$1.08M +$1.03M +51,024 New
SCM
323
Stellar Capital Management
Arizona
$1.07M -$16.3K -810 -2%
IRS
324
Invictus RG (Singapore)
Singapore
$1.07M +$413K +20,574 +69%
PP
325
PDT Partners
New York
$1.04M -$16.7M -831,216 -94%

EW Hedge Fund Activity: Q4 2014 in Review

556 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2014, worth a combined $11.7B — down 5.3% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new EW positions and 31 closed out — a net gain of 66 holders — while 193 added to existing stakes and 182 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $85M. The largest seller was Capital Research Global Investors, cutting an estimated $232M.

  • 556 institutional investors held Edwards Lifesciences (EW) as of Q4 2014, up from 496 in Q3 2014.
  • Funds reported $11.7B of Edwards Lifesciences stock for Q4 2014, down 5.3% quarter-over-quarter.
  • 97 funds opened new Edwards Lifesciences positions in Q4 2014 and 31 closed out, a net change of +66 holders.
  • The largest Edwards Lifesciences buyer in Q4 2014 was AQR Capital Management, an estimated $85M added.
  • The largest Edwards Lifesciences seller in Q4 2014 was Capital Research Global Investors, an estimated $232M sold.

Based on aggregated 13F filings for Q4 2014.